(Q38202613)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

Review of tolvaptan for autosomal dominant polycystic kidney disease (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

autosomal dominant polycystic kidney disease

13 March 2020

main subject

1 reference

based on heuristic

inferred from title

autosomal dominant polycystic kidney

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Brian P Baur

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

7 April 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

34

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

605-616

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

Clinical practice. Autosomal dominant polycystic kidney disease

13 March 2020

cites work

1 reference

Autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments

21 January 2018

1 reference

Vasopressin antagonists in polycystic kidney disease

21 January 2018

1 reference

Mechanism-based therapeutics for autosomal dominant polycystic kidney disease: recent progress and future prospects.

21 January 2018

1 reference

Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1.

21 January 2018

1 reference

Molecular genetics and pathogenesis of autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype

21 January 2018

1 reference

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

Volume progression in autosomal dominant polycystic kidney disease: the major factor determining clinical outcomes

21 January 2018

1 reference

Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study.

21 January 2018

1 reference

Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population

21 January 2018

1 reference

Renal stone disease in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials

21 January 2018

1 reference

Tolvaptan inhibits ERK-dependent cell proliferation, Cl⁻ secretion, and in vitro cyst growth of human ADPKD cells stimulated by vasopressin

21 January 2018

1 reference

Vasopressin directly regulates cyst growth in polycystic kidney disease

21 January 2018

1 reference

Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of single-dose oral tolvaptan in fasted and non-fasted states in healthy Caucasian and Japanese male subjects.

21 January 2018

1 reference

Pharmacokinetics and pharmacodynamics of oral tolvaptan in patients with varying degrees of renal function

21 January 2018

1 reference

Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects

21 January 2018

1 reference

Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.

21 January 2018

1 reference

Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.

21 January 2018

1 reference

Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort

21 January 2018

1 reference

Comparison of methods for determining renal function decline in early autosomal dominant polycystic kidney disease: the consortium of radiologic imaging studies of polycystic kidney disease cohort

21 January 2018

1 reference

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

21 January 2018

1 reference

A new equation to estimate glomerular filtration rate

21 January 2018

1 reference

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

The osmoregulation of vasopressin

21 January 2018

1 reference

Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation

21 January 2018

1 reference

Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment

21 January 2018

1 reference

A case for water in the treatment of polycystic kidney disease.

21 January 2018

1 reference

Short-term effects of tolvaptan on renal function and volume in patients with autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience

21 January 2018

1 reference

Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease

21 January 2018

1 reference

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PHAR.1421

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24706579%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference